Mandate

Vinge has advised SmartCella Holding AB in connection with fund raising

July 08, 2024 M&A

Vinge has advised SmartCella Holding AB in connection with its fund raising of EUR 50 million. The capital was invested by, among others, AstraZeneca, the Fourth Swedish National Pension Fund, AMF Pension, SEB-Stiftelsen, Handelsbanken Fonder and RoosGruppen AB. SmartCella is a world-leading biotechnology company pioneering the future of targeted therapies by combining first-in-class delivery platforms with cutting-edge cell and gene therapies.

Related

Vinge has advised Rite Ventures in connection with sale of shares in Qliro AB (publ)

Vinge has advised Rite Ventures in connection with the sale of shares in Qliro AB (publ) to Svea Bank AB (publ).
November 19, 2026

Vinge advises Röko AB (publ) in connection with the establishment of its MTN programme

Vinge has advised Röko AB (publ) ("Röko") on the establishment of a medium-term note programme (the "MTN Programme") with a framework amount of SEK 5 billion.
November 13, 2026

Vinge advises Telavox on the sale of its Nordic customer base to Telia

Vinge has advised Telavox AB (“Telavox”) on the sale of Telavox’s Nordic customer base for business services to Telia Company AB (“Telia”). The customer base comprises approximately 24,000 business customers and 325,000 end users in Sweden, Denmark, Finland, and Norway. The purchase price amounts to SEK 3.8 billion plus a potential additional earn-out.
November 13, 2026